Read below Shad, don't get wound too tight about Q2 fin's.
av8tor65 Sunday, 07/22/18 08:33:42 AM
Re: jaysolano post# 146778 0
Post # of 147457
I would expect some sort of uptick for Q2 fin's with a full quarter under NHS's belt, but not lofty $$. Wouldn't be surprised if Q3 didn't post stellar numbers. FY18 will be the "transformational" year for BIEL with NHS, FDA, Dr. Scholl's, multiple paternships/distributors promoting the product, big box deal(s)?, etc..... BUT, I believe FY19 will be the real "Blast-Off" year.
With UK NHS having a full year under its belt by this time next year, Germany kicking in also, Sweden, Dr Scholl's having its product(s) fully available(and being advertised), Migraine and Allay studies successfully completed and published(more studies too), more and more countries coming on board with NHS type deals, OTC sales beginning to increase with much needed exposure(maybe by more advertising?), US revenue streams forming, new product applications...just to say the least...its all been posted many times more eloquently than I can. Profits will continue to be made this year with the above aforementioned, but I will continue to watch BIEL grow well in to FY19 and beyond and look for the big $$. Im curious to see the 4th FY18 and 1st/2nd Qtr FY19 fin's, where significant growth should begin to be noted.
Management said "it takes time" to form partnerships and do it right, and thats exactly what they're doing! The foundation is being poured with deep footers, the BIEL Temple will soon follow.
IMO
